WHI-P180

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.

Product Specifications

CAS Number

[211555-08-7]

Product Name Alternative

Janex 3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

EGFR; RET; VEGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/whi-p180.html

Purity

99.84

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

COC1=CC2=NC=NC(NC3=CC=CC(O)=C3)=C2C=C1OC

Molecular Formula

C16H15N3O3

Molecular Weight

297.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Newton R, et al. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Eur J Med Chem. 2016 Apr 13;112:20-32.|[2]Ghosh S, et al. 4-[3-Bromo-4-hydroxyphenyl) amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvateand 4-[ (3-hydroxyphenyl) amino]-6,7-dimethoxy-1-quinazolinium chloride. Acta Crystallogr C. 2001 Jan;57 (Pt 1) :76-8.|[3]Chen CL, et al. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4- (3-hydroxyphenyl) -amino-6,7-dimethoxyquinazoline in mice. Pharm Res. 1999 Jan;16 (1) :117-22.